Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation

被引：3

作者：

Shibata, Masaru ^{[1
]}

Ezoe, Sachiko ^{[1
]}

Oritani, Kenji ^{[1
]}

Matsui, Keiko ^{[1
]}

Tokunaga, Masahiro ^{[1
]}

Fujita, Natsuko ^{[1
]}

Saito, Yuri ^{[1
]}

Takahashi, Takayuki ^{[2
]}

Hino, Masayuki ^{[3
]}

Matsumura, Itaru ^{[4
]}

Kanakura, Yuzuru ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan

[2] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan

[3] Osaka City Univ, Grad Sch Med, Dept Hematol, Osaka 558, Japan

[4] Kinki Univ, Sch Med, Dept Internal Med, Sayama, Osaka 589, Japan

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 09期

关键词：

CML; Tyrosine kinase inhibitor; Bcr-Abl; Crkl; Phosphorylation; Immunoblot; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; CYTOGENETIC RESPONSES; EUROPEAN-LEUKEMIANET; POSITIVE LEUKEMIA; BLAST CRISIS; IMATINIB; RESISTANCE; DASATINIB;

D O I：

10.1016/j.leukres.2011.01.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It would be of great value to predict the efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of individual CML patients. We propose an immunoblot system for detecting the phosphorylation of Crkl, a major target of Bcr-Abl, in blood samples after in vitro incubation with TKIs. When the remaining phosphorylated Crkl after treatment with imatinib was evaluated as the "residual index (RI)", high values were found in accordance with imatinib resistance. Moreover, RI reflected the outcome of imatinib- as well as second generation TKIs with a high sensitivity and specificity. Therefore, this system should be useful in the selection of TKIs. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1205 / 1211

页数：7

共 26 条

[1] Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].

Azam, M ;

Latek, RR ;

Daley, GQ .

CELL, 2003, 112 (06) :831-843

[2] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[3] Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study [J].

Baccarani, Michele ;

Rosti, Gianantonio ;

Castagnetti, Fausto ;

Haznedaroglu, Ibrahim ;

Porkka, Kimmo ;

Abruzzese, Elisabetta ;

Alimena, Giuliana ;

Ehrencrona, Hans ;

Hjorth-Hansen, Henrik ;

Kairisto, Veli ;

Levato, Luciano ;

Martinelli, Giovanni ;

Nagler, Arnon ;

Nielsen, Johan Lanng ;

Ozbek, Ugur ;

Palandri, Francesca ;

Palmieri, Fausto ;

Pane, Fabrizio ;

Rege-Cambrin, Giovanna ;

Russo, Domenico ;

Specchia, Giorgina ;

Testoni, Nicoletta ;

Weiss-Bjerrum, Ole ;

Saglio, Giuseppe ;

Simonsson, Bengt .

BLOOD, 2009, 113 (19) :4497-4504

[4] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles [J].

Boschelli, Diane H. ;

Wu, Biqi ;

Ye, Fei ;

Wang, Yan ;

Golas, Jennifer M. ;

Lucas, Judy ;

Boschelli, Frank .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (26) :7868-7876

[5] BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 [J].

Donato, NJ ;

Wu, JY ;

Stapley, J ;

Gallick, G ;

Lin, H ;

Arlinghaus, R ;

Talpaz, M .

BLOOD, 2003, 101 (02) :690-698

[6] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[7] GATA-2/estrogen receptor chimera regulates cytokine-dependent growth of hematopoietic cells through accumulation of p21WAF1 and p27Kip1 proteins [J].

Ezoe, S ;

Matsumura, I ;

Nakata, S ;

Gale, K ;

Ishihara, K ;

Minegishi, N ;

Machii, T ;

Kitamura, T ;

Yamamoto, M ;

Enver, T ;

Kanakura, Y .

BLOOD, 2002, 100 (10) :3512-3520

[8] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[9] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [J].

Kantarjian, Hagop ;

Shah, Neil P. ;

Hochhaus, Andreas ;

Cortes, Jorge ;

Shah, Sandip ;

Ayala, Manuel ;

Moiraghi, Beatriz ;

Shen, Zhixiang ;

Mayer, Jiri ;

Pasquini, Ricardo ;

Nakamae, Hirohisa ;

Huguet, Francoise ;

Boque, Concepcion ;

Chuah, Charles ;

Bleickardt, Eric ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Szatrowski, Ted ;

Shapiro, David ;

Baccarani, Michele .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2260-2270

[10] NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia [J].

Kimura, S ;

Naito, H ;

Segawa, H ;

Kuroda, J ;

Yuasa, T ;

Sato, K ;

Yokota, A ;

Kamitsuji, Y ;

Kawata, E ;

Ashihara, E ;

Nakaya, Y ;

Naruoka, H ;

Wakayama, T ;

Nasu, K ;

Asaki, T ;

Niwa, T ;

Hirabayashi, K ;

Maekawa, T .

BLOOD, 2005, 106 (12) :3948-3954

← 1 2 3 →